The Present and Future of Inflammatory Bowel Disease Treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis.Frontiers in immunology · 2018
   Trial
2. Therapeutic effect of Sheng Mai San, a traditional Chinese medicine formula, on inflammatory bowel disease via inhibition of NF-κB and NLRP3 inflammasome signaling.Frontiers in pharmacology · 2024
   Article
3. Immunoglobulin A Glycosylation Differs between Crohn's Disease and Ulcerative Colitis.Journal of proteome research · 2023
   Article
4. Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease.Tissue engineering and regenerative medicine · 2023
   Article
5. Inhibition of IRAK 1/4 alleviates colitis by inhibiting TLR4/ NF-κB pathway and protecting the intestinal barrier.Bosnian journal of basic medical sciences · 2022
   Article
6. Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells.Frontiers in immunology · 2022
   Article
7. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.BMC gastroenterology · 2021
   Article
8. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.BMC gastroenterology · 2020
   Article
9. Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease.Cells · 2020
   Review
10. Baseline levels of dynamic CD4BMC gastroenterology · 2020
    Article
11. The recruitment of extra-intestinal cells to the injured mucosa promotes healing in radiation enteritis and chemical colitis in a mouse parabiosis model.Mucosal immunology · 2019
    Article
12. Endoscopy in inflammatory bowel disease: from guidelines to real life.Therapeutic advances in gastroenterology · 2019
    Review
13. Biologic treatment of Japanese patients with inflammatory bowel disease.BMC gastroenterology · 2018
    Article
14. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.Mucosal immunology · 2018
    Review
15. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.Journal of inflammation research · 2018
    Review
16. The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.Inflammatory intestinal diseases · 2017
    Article
17. Frontiers in Drug Research and Development for Inflammatory Bowel Disease.Frontiers in pharmacology · 2017
    Review
18. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.Drug design, development and therapy · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.